AFP and cancer: Further, Ha2bm promoter-driven oncolytic Ad elicited more potent reduction in viability of cancer cells than hypoxia-responsive full human AFP promoter-driven oncolytic Ad (HRE6-hAFP-d1940) in AFP-positive HCC cells (Fig. S2B), suggesting that deletion of the silencers and insertion of the extra EA region to enhancer region containing single EB can greatly augment the transcriptional activity of the AFP promoter (Fig. 1).